RxDoctor Payments Data

Michael Rusche, MD

Gastroenterology · Newburgh, INNPI 1659301760

Payments from drug & device makers

$2,486in general payments, 2019–2025

Across 89 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bristol Myers Squibb$555
  • Johnson & Johnson$303
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$149
  • E.r. Squibb & Sons, L.L.C.$123
  • Janssen Scientific Affairs, LLC$113
  • plus $195 from 6 others

What the payments were for

  • Food & beverage$2,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,486 in reported general payments places this provider in the 50th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$419,949
Medicare patients
804
Services billed
7,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab55$1,418,902
Skyrizi On-BodyRisankizumab-Rzaa25$493,804
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates284$19,641
LinzessLinaclotide22$12,632
ClenpiqSod Picosulf/Mag Ox/Citric Ac64$11,073
MotegrityPrucalopride Succinate18$9,799
Mesalamine25$9,163
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,729
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg152$2,945
Pantoprazole Sodium144$1,865
Omeprazole78$702
Sucralfate13$668
Esomeprazole Magnesium17$616
Hydrocortisone13$170
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$303$1,418,90255 claims
AbbVieLinzess$1,049$12,63222 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$16$9,79918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →